Optimizing Research with Decentralized Strategies
DECENTRALIZED, DIGITALLY ENABLED, DIRECT-TO-PATIENT
As COVID-19 changes the playing field and accelerates different approaches in clinical trials, it’s good to know the latest insights. As a global CRO, PPD is committed to partnering with organizations to navigate evolving trends in drug development to optimize the delivery of life-changing therapies.
With regulatory bodies recognizing the immediate threat of the pandemic to clinical research, we have seen encouragement of the decentralization and digitization of trials. But even outside of COVID-19 risk mitigation, this approach to trials makes participation more convenient and therefore appealing for patients and their loved ones. PPD has consequently been building solutions for this evolution for a long time.
Decentralized Solutions from PPD
Complimentary insights from PPD covering metrics, services and digital technologies supporting decentralized trial research.
WHAT YOU NEED TO KNOW TODAY
We are seeing unprecedented changes since the appearance of the SARS-CoV-2 virus, but the trend towards decentralized trials was already underway prior to COVID-19. The pandemic is changing research conditions for both sites and patients, dramatically affecting the continuity of trials globally.
With this sudden disruption, the industry has been introduced to new regulatory guidelines designed to keep drug development on track and ensure trials meet critical milestones in the face of logistical and operational hurdles.
As a trusted leader in the decentralized trial space, PPD frequently publishes insights into these trends, the solutions that are available, and what the options and best approaches are for sponsors with ongoing and planned clinical trials. We invite you to click on the link below to read a newly published perspective.
PROTECTING CLINICAL RESEARCH AND PATIENTS THROUGH DECENTRALIZED TRIAL STRATEGIES
Download the articleSolutions
